Perspective: Minimal clinically important difference (MCID) and Alzheimer's disease clinical trials
Abstract The minimum clinically important difference (MCID) is a measure of the minimal clinically relevant change. The MCID represents the smallest difference in score on the measure or domain of interest which patients or clinicians perceive as beneficial or as meaningful decline. The MCID is not...
Saved in:
| Main Author: | Jeffrey Cummings |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.70059 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The minimal clinically important difference changes greatly based on the patient's baseline clinical status
by: Marco Franceschini, et al.
Published: (2025-01-01) -
Estimating a minimum clinically important difference for the Developmental Behaviour Checklist – parent report
by: Daniel L. Sutherland, et al.
Published: (2025-08-01) -
Low-dose interleukin-2 in patients with mild to moderate Alzheimer’s disease: a randomized clinical trial
by: Alireza Faridar, et al.
Published: (2025-07-01) -
Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer’s disease
by: Valentina R. Garbarino, et al.
Published: (2025-07-01) -
Importance of clinical trials and contributions to contemporary medicine: commentary
by: Haofuzi Zhang, et al.
Published: (2025-12-01)